PMID- 33140575
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 23
IP  - 2
DP  - 2021 Feb
TI  - Patients' preferences for once-daily oral versus once-weekly injectable diabetes 
      medications: The REVISE study.
PG  - 508-519
LID - 10.1111/dom.14244 [doi]
AB  - AIMS: To understand patient preferences for once-daily oral versus once-weekly 
      injectable type 2 diabetes mellitus (T2DM) medication administration profiles, 
      and reasons for their preferences. MATERIALS AND METHODS: The REVISE study, a 
      cross-sectional online survey of 600 participants with T2DM (United Kingdom, n = 
      300; United States, n = 300), elicited general preferences for once-daily oral 
      versus once-weekly injectable diabetes medications, and reasons for the 
      preference. Participants then viewed two videos describing the administration 
      procedures for injectable dulaglutide and oral semaglutide, based on the product 
      instructions for use. Thereafter, participants indicated their preference for a 
      once-weekly injectable or a once-daily oral medication based on the video 
      descriptions. Participants who switched preferences were asked to identify the 
      reasons influencing their decision. RESULTS: The participants were predominantly 
      male (n = 349; 58.2%), with a mean (SD) age of 64 (11.3) years. Nearly all (n = 
      557; 92.8%) were taking an oral T2DM medication, and 158 (26.3%) were using an 
      injectable. Initially, 76.5% (n = 459; 95% confidence interval [CI] 73.1-79.9) 
      preferred a once-daily oral and 23.5% a once-weekly injectable (n = 141; 95% CI 
      20.1-26.9; P < 0.0001). After viewing the videos describing the product-specific 
      administration, the proportions of participants preferring each option were not 
      statistically different (oral semaglutide administration description (n = 315; 
      52.5%; 95% CI 48.5-56.5; dulaglutide administration description (n = 285; 47.5%; 
      95% CI 43.5-51.5; NS, P = 0.2207). The most common reason for switching 
      preferences was the timing and steps of administration. CONCLUSION: Several 
      treatment-related characteristics, including route, frequency and complexity of 
      the treatment, play a role in patients' preferences for T2DM treatments and 
      should be considered during treatment selection.
CI  - (c) 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Boye, Kristina
AU  - Boye K
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Ross, Melissa
AU  - Ross M
AUID- ORCID: 0000-0001-7317-9273
AD  - Evidera Inc, Bethesda, Maryland, USA.
FAU - Mody, Reema
AU  - Mody R
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Konig, Manige
AU  - Konig M
AD  - Eli Lilly and Company, Indianapolis, Indiana, USA.
FAU - Gelhorn, Heather
AU  - Gelhorn H
AUID- ORCID: 0000-0003-3566-1004
AD  - Evidera Inc, Bethesda, Maryland, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201213
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptides
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Male
MH  - Middle Aged
MH  - *Patient Preference
MH  - United Kingdom/epidemiology
PMC - PMC7839441
OTO - NOTNLM
OT  - United Kingdom
OT  - United States
OT  - daily oral
OT  - preferences
OT  - type 2 diabetes
OT  - weekly injectable
COIS- Melissa Ross and Heather Gelhorn - nothing to disclose. Reema Mody, Manige Konig, 
      and Kristina Boye are minor shareholders and employees of Eli Lilly and Company.
EDAT- 2020/11/04 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/01/27
CRDT- 2020/11/03 05:52
PHST- 2020/07/07 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/11/03 05:52 [entrez]
PHST- 2021/01/27 00:00 [pmc-release]
AID - DOM14244 [pii]
AID - 10.1111/dom.14244 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2021 Feb;23(2):508-519. doi: 10.1111/dom.14244. Epub 2020 
      Dec 13.